McKesson Corporation (MCK)

From the record

McKesson Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

McKesson Corporation's 10 filed years say what it did: revenue went from $199 billion in fiscal 2017 to $403 billion in fiscal 2026, up 8.2% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 9 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-03-31, McKesson Corporation's diluted share count shrank about 4.4% a year, and dividends and buybacks returned about 72% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 21 sales (19 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-06 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-03-31, McKesson Corporation's shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 18 cents per dollar of everything the company owns. Leverage: it owed about 102 cents per dollar of assets, and net share issuance: its share count shrank 3.1% over the year (the filed statements).

From the record

McKesson Corporation's standing among 10 graded names in its industry family: revenue of $403 billion in fiscal 2026 ranks in the top 5% by size; a net margin of 1.2% ranks in the top 25%; revenue growth of 13.4% a year over the last 3 filed years ranks in the top 25% (its annual reports).

From the record

McKesson Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Tyler, Brian Scott (Chief Executive Officer, as filed), filing under that title since 2019-05-23, 7.5 years (top 17% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 4.6 years (top 36%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (top 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

McKesson Corporation's room to grow, from the newest filed statements (fiscal 2026): cash of $4.0 billion against debt of $6.5 billion leaves -3.1% of its assets as net cash, top 25% of its family; cash from operations less capital spending is 1.4% of revenue (top 45%); a gross margin of 3.6% (bottom 25%) (its annual report).

From the record

McKesson Corporation's growth drivers, from the filed years to fiscal 2026: revenue grew 13.4% a year over the last three filed years against 8.2% over all 10, speeding up (top 6% of its family); the newest year grew 12.4% (top 44%); research spending grew -34.5% a year (bottom 13%); capital spending grew 3.8% a year (top 31%) (its annual reports). McKesson Corporation reported 4 lines of business in fiscal 2025: US Pharmaceutical at $328 billion, International at $15 billion, Medical Surgical Solutions at $11 billion, and 1 more. 4 of 4 grew in the latest filed year, and the largest line is 91% of revenue (its annual report).

From the record

McKesson Corporation's newest year against its own record: revenue of $403 billion in fiscal 2026 came in 1.4% below the $409 billion its prior three years' pace pointed to (top 50% of its family); net income of $4.8 billion against a prior three-year average of $3.3 billion (top 36%); a net margin of 1.2% against 1.1% before (top 50%) (its annual reports).